View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Appoints Japan-Based Non-Executive Director with Extensive Pharmaceutical Industry Experience

🕔12/11/2017 9:59:39 AM 714

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of Leo Lee as an independent non-executive director of Regeneus with effect from December.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders and CEO Presentation

🕔11/2/2017 12:58:57 PM 1689

Regeneus Ltd (ASX:RGS) provides the Company's Chairman's address to shareholders and CEO presentation at 2017 Annual General Meeting.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation on Japan First Strategy at Ord Minnett

🕔11/1/2017 12:41:09 PM 1556

Regeneus Ltd (ASX:RGS) provides the Company's Presentation on Japan First Strategy at Ord Minnett.

Read Full Article

Regeneus Ltd (ASX:RGS) Sygenus Shows Longer Lasting Effect on Pain than Morphine

🕔9/26/2017 9:29:00 AM 1987

Regeneus Ltd (ASX:RGS) , a clinical-stage regenerative medicine company, today announced that a preclinical post-operative pain study has shown that topical application of Sygenus, has significantly greater and longer lasting analgesic effect than an injection of morphine.

Read Full Article

Regeneus Ltd (ASX:RGS) Edison Investment Report Issued

🕔9/11/2017 7:52:04 AM 1993

The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.6m

🕔8/29/2017 11:29:46 AM 1681

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.

Read Full Article

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) Interview with John Martin on Progenza and the Platform Technology

🕔8/25/2017 10:15:41 AM 5355

Regeneus Ltd (ASX:RGS) CEO John Martin talks on the release of the financial results following the company's significant progress with Japanese partner Asahi Glass Ltd (AGC) (TYO:5201)

Read Full Article

Regeneus Ltd (ASX:RGS) FY17 Results Announcement

🕔8/22/2017 9:57:16 AM 2128

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Full-Year Report for the 12 months ending 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔7/26/2017 9:30:49 AM 1833

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent Allowed for Sygenus Secretions Technology for Acne

🕔7/10/2017 9:26:34 AM 1792

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for a patent covering the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus, to treat acne. We recently informed the market of the new name for the secretions platform in our Q2 2017 Update.

Read Full Article
###

61,262 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 356) (Last 30 Days: 1288) (Since Published: 32102) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media